InnoCare Pharma Wins NMPA Approval for Phase II Trial of TYK2 Inhibitor in Cutaneous Lupus Erythematosus
I'm PortAI, I can summarize articles.
InnoCare Pharma Ltd. has received approval from the China National Medical Products Administration to conduct a phase II clinical trial of its TYK2 inhibitor, ICP-488, for treating cutaneous lupus erythematosus. This approval follows positive results in psoriasis trials, aiming to offer a convenient treatment for autoimmune diseases. The news was published by InnoCare Pharma via GlobeNewswire on December 23, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments